N. Andreasen, S. Arndt, R. Alliger, D. Miller, and M. Flaum, Symptoms of Schizophrenia, Archives of General Psychiatry, vol.52, issue.5, pp.341-51, 1995.
DOI : 10.1001/archpsyc.1995.03950170015003

I. Bratti, J. Kane, and S. Marder, Chronic Restlessness With Antipsychotics, American Journal of Psychiatry, vol.164, issue.11, pp.1648-54, 2007.
DOI : 10.1176/appi.ajp.2007.07071150

D. Robinson, M. Woerner, J. Alvir, R. Bilder, R. Goldman et al., Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder, Archives of General Psychiatry, vol.56, issue.3, p.241, 1999.
DOI : 10.1001/archpsyc.56.3.241

A. Lagodka and D. Ginestet, Histoire des Neuroleptiques d'action prolong??e, L'Enc??phale, vol.34, pp.226-257, 2008.
DOI : 10.1016/S0013-7006(08)75519-2

A. Lostia, L. Mazzarini, I. Pacchiarotti, L. Lionetto, D. Rossi et al., Serum Levels of Risperidone and Its Metabolite, 9-Hydroxyrisperidone: Correlation Between Drug Concentration and Clinical Response, Therapeutic Drug Monitoring, vol.31, issue.4, pp.475-81, 2009.
DOI : 10.1097/FTD.0b013e3181aa4780

J. Leysen, W. Gommeren, A. Eens, D. De-chaffoy-de-courcelles, J. Stoof et al., Biochemical profile of risperidone, a new antipsychotic, J Pharmacol Exp Ther. nov, vol.247, issue.2, pp.661-70, 1988.

P. Janssen, C. Niemegeers, F. Awouters, K. Schellekens, A. Megens et al., Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties, J Pharmacol Exp Ther. févr, vol.244, issue.2, pp.685-93, 1988.

T. Kuroki, N. Nagao, and T. Nakahara, Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin???dopamine hypothesis, In: Progress in Brain Research [Internet], 2008.
DOI : 10.1016/S0079-6123(08)00910-2

E. Mannaert, A. Vermeulen, B. Remmerie, P. Bouhours, and J. Levron, Pharmacokinetic profile of long-acting injectable risperidone at steady-state : comparison with oral administration, L'Enc??phale, vol.31, issue.5, pp.609-624, 2005.
DOI : 10.1016/S0013-7006(05)82420-0

M. Huang, J. Shentu, J. Chen, J. Liu, and H. Zhou, Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers, Journal of Zhejiang University SCIENCE B, vol.9, issue.2, pp.114-134, 2008.
DOI : 10.1631/jzus.B0710439

M. Cánovas, J. Delgadillo, F. Torres, N. Riba, J. Cebrecos et al., Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers, Int. Journal of Clinical Pharmacology and Therapeutics, vol.47, issue.02, pp.124-155, 2009.
DOI : 10.5414/CPP47124

M. Aravagiri, S. Marder, K. Nuechterlein, and M. Gitlin, Intra- and Interindividual Variations in Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients Treated Chronically with Various Doses of Risperidone, Therapeutic Drug Monitoring, vol.25, issue.6, pp.657-64, 2003.
DOI : 10.1097/00007691-200312000-00003

J. Leysen, P. Janssen, A. Megens, and A. Schotte, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity, J Clin Psychiatry. mai, vol.55, pp.5-12, 1994.

R. Nesvåg, M. Hendset, H. Refsum, and L. Tanum, Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication, Acta Psychiatrica Scandinavica, vol.156, issue.1, pp.21-27, 2006.
DOI : 10.1016/j.eurpsy.2003.11.007

N. Bozina, N. Jovanovi?, M. Lovri?, and V. Medved, Clinical Significance of a CYP2D6 Poor Metabolizer -A Patient With Schizophrenia on Risperidone Treatment, Therapeutic Drug Monitoring, vol.30, issue.6, pp.748-51, 2008.
DOI : 10.1097/FTD.0b013e3181896afc

R. Kang, S. Jung, K. Kim, D. Lee, H. Cho et al., Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients, Journal of Clinical Psychopharmacology, vol.29, issue.3, pp.272-279, 2009.
DOI : 10.1097/JCP.0b013e3181a289e0

J. De-leon, G. Wynn, and N. Sandson, The Pharmacokinetics of Paliperidone Versus Risperidone, Psychosomatics, vol.51, issue.1, pp.80-88, 2010.
DOI : 10.1016/S0033-3182(10)70664-2

D. Ravyn, V. Ravyn, R. Lowney, and H. Nasrallah, CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence, Schizophrenia Research, vol.149, issue.1-3, pp.1-14, 2013.
DOI : 10.1016/j.schres.2013.06.035

T. Prior and G. Baker, Interactions between the cytochrome P450 system and the secondgeneration antipsychotics, J Psychiatry Neurosci JPN. mars, vol.28, issue.2, pp.99-112, 2003.

E. Spina, A. Avenoso, G. Facciolà, M. Salemi, M. Scordo et al., Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication With Carbamazepine or Valproate, Therapeutic Drug Monitoring, vol.22, issue.4, pp.481-486, 2000.
DOI : 10.1097/00007691-200008000-00019

N. Yasui-furukori, M. Hidestrand, E. Spina, G. Facciolá, M. Scordo et al., Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes, Drug Metab Dispos Biol Fate Chem. oct, vol.29, issue.10, pp.1263-1271, 2001.

A. Serretti, A. Chiesa, R. Calati, C. Fabbri, O. Sentissi et al., Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples, Journal of Psychopharmacology, vol.39, issue.7, pp.616-644, 2013.
DOI : 10.1037/0022-3514.54.6.1020

D. Casey, Side effect profiles of new antipsychotic agents, J Clin Psychiatry, vol.57, issue.11, pp.40-45, 1996.

G. Ostuzzi, I. Bighelli, R. So, T. Furukawa, and C. Barbui, Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies, Schizophrenia Research, vol.183, pp.10-21, 2017.
DOI : 10.1016/j.schres.2016.11.010

B. Kinon, J. Gilmore, H. Liu, and U. Halbreich, Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone11This work was sponsored by Eli Lilly and Company., Psychoneuroendocrinology, vol.28, issue.2, pp.55-68, 2003.
DOI : 10.1016/S0306-4530(02)00127-0

J. Buvat, Hyperprolactinemia and sexual function in men: a short review, International Journal of Impotence Research, vol.353, issue.Suppl 1, pp.373-380, 2003.
DOI : 10.1016/S0140-6736(05)74947-3

P. Kadioglu, A. Yalin, O. Tiryakioglu, N. Gazioglu, G. Oral et al., SEXUAL DYSFUNCTION IN WOMEN WITH HYPERPROLACTINEMIA: A PILOT STUDY REPORT, The Journal of Urology, vol.174, issue.5, pp.1921-1926, 2005.
DOI : 10.1097/01.ju.0000176456.50491.51

H. Liu-seifert, B. Kinon, C. Tennant, J. Sniadecki, and J. Volavka, Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone, Neuropsychiatric Disease and Treatment, vol.5, pp.47-54, 2009.
DOI : 10.2147/NDT.S4766

A. Riecher-rössler, C. Schmid, S. Bleuer, and M. Birkhäuser, Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy], Neuropsychiatr Klin Diagn Ther Rehabil Organ Ges Osterreichischer Nervenarzte Psychiater, vol.23, issue.2, pp.71-83, 2009.

J. Bostwick, S. Guthrie, and V. Ellingrod, Antipsychotic-Induced Hyperprolactinemia, Pharmacotherapy, vol.89, issue.1, pp.64-73, 2009.
DOI : 10.1016/j.schres.2004.12.004

D. Allison and D. Casey, Antipsychotic-induced weight gain: a review of the literature, J Clin Psychiatry, vol.62, pp.22-31, 2001.

S. Chabroux, E. Haffen, and A. Penfornis, Diab??te et antipsychotiques de seconde g??n??ration, Annales d'Endocrinologie, vol.70, issue.4, pp.202-212, 2009.
DOI : 10.1016/j.ando.2009.07.003

S. Sood, W. James, and M. Bailon, Priapism associated with atypical antipsychotic medications: a review, International Clinical Psychopharmacology, vol.23, issue.1, pp.9-17, 2008.
DOI : 10.1097/YIC.0b013e3282f1c1ef

J. Nandagopal, J. Craig, and S. Lippmann, QTc Prolongation: Possible Association With Risperidone and/or Haloperidol, Psychosomatics, vol.44, issue.6, p.521, 2003.
DOI : 10.1176/appi.psy.44.6.521

P. Gajwani, K. Franco-bronson, and G. Tesar, Risperidone-Induced Sialorrhea, Psychosomatics, vol.42, issue.3, p.276, 2001.
DOI : 10.1176/appi.psy.42.3.276

S. Khaldi, C. Kornreich, Z. Choubani, and R. Gourevitch, Antipsychotiques atypiques et syndrome malin des neuroleptiques??: br??ve revue de la litt??rature, L'Enc??phale, vol.34, issue.6, pp.618-642, 2008.
DOI : 10.1016/j.encep.2007.11.007

A. Loonen, C. Doorschot, M. Oostelbos, and J. Sitsen, Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study, European Neuropsychopharmacology, vol.10, issue.1, pp.51-58, 1999.
DOI : 10.1016/S0924-977X(99)00054-1

F. Huang, K. Lasseter, L. Janssens, T. Verhaeghe, H. Lau et al., Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together, The Journal of Clinical Pharmacology, vol.314, issue.7076, pp.1341-51, 2002.
DOI : 10.1136/bmj.314.7076.266

J. Demling, M. Huang, B. Remmerie, E. Mannaert, and W. Sperling, Pharmacokinetics and Safety of Combination Therapy with Lithium and Risperidone, Pharmacopsychiatry, vol.39, issue.6, pp.230-231, 2006.
DOI : 10.1055/s-2006-950394

G. Migliardi, D. Arrigo, C. Santoro, V. Bruno, A. et al., Effect of Topiramate on Plasma Concentrations of Clozapine, Olanzapine, Risperidone, and Quetiapine in Patients With Psychotic Disorders, Clinical Neuropharmacology, vol.30, issue.2, pp.107-120, 2007.
DOI : 10.1097/01.wnf.0000240955.49315.65

M. Mula and F. Monaco, Carbamazepine???Risperidone Interactions in Patients With Epilepsy, Clinical Neuropharmacology, vol.25, issue.2, pp.97-100, 2002.
DOI : 10.1097/00002826-200203000-00007

C. Darrigo, G. Migliardi, V. Santoro, L. Morgante, M. Muscatello et al., Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia, Pharmacological Research, vol.52, issue.6, pp.497-501, 2005.
DOI : 10.1016/j.phrs.2005.09.005

E. Spina, D. Arrigo, C. Migliardi, G. Morgante, L. Zoccali et al., Plasma Risperidone Concentrations During Combined Treatment with Sertraline, Therapeutic Drug Monitoring, vol.26, issue.4, pp.386-90, 2004.
DOI : 10.1097/00007691-200408000-00008

E. Spina, A. Avenoso, M. Scordo, M. Ancione, A. Madia et al., Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: A Clinically Relevant Pharmacokinetic Drug Interaction, Journal of Clinical Psychopharmacology, vol.22, issue.4, pp.419-442, 2002.
DOI : 10.1097/00004714-200208000-00014

M. Saito, N. Yasui-furukori, T. Nakagami, H. Furukori, and S. Kaneko, Dose-Dependent Interaction of Paroxetine With Risperidone in Schizophrenic Patients, Journal of Clinical Psychopharmacology, vol.25, issue.6, pp.527-559, 2005.
DOI : 10.1097/01.jcp.0000185428.02430.c7

U. Jeppesen, L. Gram, K. Vistisen, S. Loft, H. Poulsen et al., Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine, European Journal of Clinical Pharmacology, vol.51, issue.1, pp.73-81, 1996.
DOI : 10.1007/s002280050163

J. Amchin, W. Zarycranski, K. Taylor, D. Albano, and P. Klockowski, Effect of venlafaxine on the pharmacokinetics of risperidone, J Clin Pharmacol. mars, vol.39, issue.3, pp.297-309, 1999.

M. Lee, H. Lee, and L. Kim, A Case of Delayed NMS Induced by Risperidone, Psychiatric Services, vol.51, issue.2, pp.254-259, 2000.
DOI : 10.1176/appi.ps.51.2.254-a

S. Jung, K. Kim, H. Cho, I. Jung, P. Park et al., Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients, Clinical Pharmacology & Therapeutics, vol.78, issue.5, pp.520-528, 2005.
DOI : 10.1016/j.clpt.2005.07.007

E. Cousein, C. Barthélémy, S. Poullain, N. Simon, S. Lestavel et al., P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.31, issue.4, pp.878-86, 2007.
DOI : 10.1016/j.pnpbp.2007.01.028

R. Yoshimura, K. Shinkai, N. Ueda, and J. Nakamura, Valproic Acid improves Psychotic Agitation without Influencing Plasma Risperidone Levels in Schizophrenic Patients, Pharmacopsychiatry, vol.40, issue.1, pp.9-13, 2007.
DOI : 10.1055/s-2007-958521

R. Muscatello, M. Pacetti, M. Cacciola, M. , L. Torre et al., Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine, Epilepsia, vol.29, issue.5, pp.771-775, 2005.
DOI : 10.1358/dot.2003.39.7.799445

K. Kim, P. Park, K. Liu, K. Kim, H. Lee et al., Effect of Rifampin, an Inducer of CYP3A and P-glycoprotein, on the Pharmacokinetics of Risperidone, The Journal of Clinical Pharmacology, vol.45, issue.1, pp.66-72, 2008.
DOI : 10.1046/j.1365-2125.1998.t01-1-00698.x

R. Yoshimura, K. Shinkai, S. Kakihara, M. Goto, Y. Yamada et al., Little Effects of Low Dosage of Levomepromazine on Plasma Risperidone Levels, Pharmacopsychiatry, vol.38, issue.2, pp.98-100, 2005.
DOI : 10.1055/s-2005-837811

J. Reyes, S. Preskorn, A. Khan, D. Kumar, E. Cullen et al., Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses, British Journal of Clinical Pharmacology, vol.92, issue.s1, pp.50-57, 2004.
DOI : 10.1038/clpt.1993.146

E. Spina, D. Arrigo, C. Migliardi, G. Santoro, V. Muscatello et al., Effect of Adjunctive Lamotrigine Treatment on the Plasma Concentrations of Clozapine, Risperidone and Olanzapine in Patients With Schizophrenia or Bipolar Disorder, Therapeutic Drug Monitoring, vol.28, issue.5, pp.599-602, 2006.
DOI : 10.1097/01.ftd.0000246763.59506.b0

Y. Nazirizadeh, F. Vogel, W. Bader, E. Haen, B. Pfuhlmann et al., Serum concentrations of paliperidone versus risperidone and clinical effects, European Journal of Clinical Pharmacology, vol.163, issue.3, pp.797-803, 2010.
DOI : 10.1176/ajp.156.6.869

URL : https://hal.archives-ouvertes.fr/hal-00582164

M. Corena-mcleod, Comparative Pharmacology of Risperidone and Paliperidone, Drugs in R&D, vol.103, issue.6, pp.163-74, 2015.
DOI : 10.1016/S0091-6749(99)70174-0

M. Kramer, R. Litman, D. Hough, R. Lane, P. Lim et al., Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study, The International Journal of Neuropsychopharmacology, vol.13, issue.05, pp.635-682, 2010.
DOI : 10.1017/S1461145709990988

M. Samtani, A. Vermeulen, and K. Stuyckens, Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia, Clinical Pharmacokinetics, vol.3, issue.2, pp.585-600, 2009.
DOI : 10.1248/cpb.29.1410

C. Dolder, M. Nelson, and Z. Deyo, Paliperidone for schizophrenia. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 mars, pp.403-416, 2008.

S. Gentile, Conclusion, Hormone Molecular Biology and Clinical Investigation, vol.61, issue.0, 2017.
DOI : 10.1515/hmbci-2017-0004

J. Peuskens, G. Rubio, and A. Schreiner, Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice, Annals of General Psychiatry, vol.13, issue.1, p.10, 2014.
DOI : 10.1017/S1461145709990988

M. Samtani, S. Gopal, C. Gassmann-mayer, L. Alphs, and J. Palumbo, Dosing and Switching Strategies for Paliperidone Palmitate, CNS Drugs, vol.25, issue.10, pp.829-874, 2011.
DOI : 10.2165/11591690-000000000-00000

C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier et al., AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update, Pharmacopsychiatry. sept, vol.44, issue.06, pp.195-235, 2011.

C. Hiemke, Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology, Current Drug Delivery, vol.13, issue.3, pp.353-61, 2016.
DOI : 10.2174/1567201812666151029100909

M. Riedel, M. Schwarz, M. Strassnig, I. Spellmann, A. Müller-arends et al., Risperidone plasma levels, clinical response and side???effects, European Archives of Psychiatry and Clinical Neuroscience, vol.7, issue.4, pp.261-269, 2005.
DOI : 10.4088/JCP.v60n0801

A. Balant-gorgia, M. Gex-fabry, C. Genet, and L. Balant, Therapeutic Drug Monitoring of Risperidone Using a New, Rapid HPLC Method: Reappraisal of Interindividual Variability Factors, Therapeutic Drug Monitoring, vol.21, issue.1, pp.105-120, 1999.
DOI : 10.1097/00007691-199902000-00017

K. Melkersson, Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite, Human Psychopharmacology: Clinical and Experimental, vol.185, issue.8, pp.529-561, 2006.
DOI : 10.1002/hup.811

P. Odou, J. Levron, M. Luyckx, C. Brunet, and H. Robert, Risperidone Drug Monitoring, Clinical Drug Investigation, vol.21, issue.2, pp.283-92, 2000.
DOI : 10.2165/00044011-200019040-00006

P. Baumann, C. Hiemke, S. Ulrich, G. Eckermann, I. Gaertner et al., The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry, Pharmacopsychiatry, vol.37, issue.6, pp.243-65, 2004.
DOI : 10.1055/s-2004-832687

R. Woestenborghs, W. Lorreyne, F. Van-rompaey, and J. Heykants, Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.583, issue.2, pp.223-253, 1992.
DOI : 10.1016/0378-4347(92)80556-6

O. Olesen and L. K. , Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs, Journal of Chromatography B: Biomedical Sciences and Applications, vol.698, issue.1-2, pp.209-225, 1997.
DOI : 10.1016/S0378-4347(97)00302-2

T. Nagasaki, T. Ohkubo, K. Sugawara, N. Yasui, H. Furukori et al., Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia, Journal of Pharmaceutical and Biomedical Analysis, vol.19, issue.3-4, pp.595-601, 1999.
DOI : 10.1016/S0731-7085(98)00261-1

A. Avenoso, G. Facciolà, M. Salemi, and E. Spina, Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection, Journal of Chromatography B: Biomedical Sciences and Applications, vol.746, issue.2, pp.173-81, 2000.
DOI : 10.1016/S0378-4347(00)00323-6

K. Titier, E. Déridet, E. Cardone, A. Abouelfath, and N. Moore, Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose, Journal of Chromatography B, vol.772, issue.2, pp.373-381, 2002.
DOI : 10.1016/S1570-0232(02)00091-0

C. Frahnert, M. Rao, and K. Grasmäder, Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring, Journal of Chromatography B, vol.794, issue.1, pp.35-47, 2003.
DOI : 10.1016/S1570-0232(03)00393-3

A. Llerena, R. Berecz, P. Dorado, . De, C. Garza et al., Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions, Journal of Chromatography B, vol.783, issue.1, pp.213-222, 2003.
DOI : 10.1016/S1570-0232(02)00661-X

G. Zhang, A. Terry, and M. Bartlett, Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma, Rapid Communications in Mass Spectrometry, vol.11, issue.6, pp.920-928, 2007.
DOI : 10.1001/archpsyc.1992.01820050018002

T. Jones, K. Van-breda, C. B. Dean, A. Mcdermott, B. Norris et al., Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders, Biomedical Chromatography, vol.583, issue.9, pp.929-963, 2009.
DOI : 10.1002/bmc.1204

C. Alamo and F. López-muñoz, The pharmacological role and clinical applications of antipsychotics' active metabolites: paliperidone versus risperidone, Clin Exp Pharmacol. 1 janv, vol.3, 2013.

M. Hanley, D. Abernethy, and D. Greenblatt, Effect of Obesity on the Pharmacokinetics of Drugs in Humans, Clinical Pharmacokinetics, vol.16, issue.5 Pt 1, pp.71-87, 2010.
DOI : 10.1097/01.AOG.0000149155.11912.52

P. Han, S. Duffull, C. Kirkpatrick, and B. Green, Dosing in Obesity: A Simple Solution to a Big Problem, Clinical Pharmacology & Therapeutics, vol.61, issue.5, pp.505-513, 2007.
DOI : 10.1038/sj.clpt.6100381

J. Kane, Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies, J Clin Psychiatry, vol.64, pp.34-40, 2003.

S. Keith and J. Kane, Partial Compliance and Patient Consequences in Schizophrenia, The Journal of Clinical Psychiatry, vol.64, issue.11, pp.1308-1323, 2003.
DOI : 10.4088/JCP.v64n1105

H. Nasrallah, The case for long-acting antipsychotic agents in the post-CATIE era, Acta Psychiatrica Scandinavica, vol.65, issue.5, pp.260-267, 2007.
DOI : 10.1111/j.1600-0447.2006.00766.x

S. Preskorn and G. Fast, Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness, J Clin Psychiatry. juin, vol.52, pp.23-33, 1991.

D. Touw, C. Neef, A. Thomson, and A. Vinks, Cost-Effectiveness of Therapeutic Drug Monitoring, Therapeutic Drug Monitoring, vol.27, issue.1, pp.10-17, 2005.
DOI : 10.1097/00007691-200502000-00004